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nificant ESs were found for all 3 outcome domains (ES range: 
0.13–0.19, all p < 0.05). Psychological interventions were 
more beneficial for physical symptoms when delivered by 
PTs than by GPs (p = 0.02). There was no difference between 
PTs and GPs in terms of physical functioning and psycho-
logical symptoms.  Conclusion: Psychological interventions 
are effective for patients with MUS, but the effects are small 
and most likely of short duration. Interventions that are de-
livered by PTs appear to have larger effects on unexplained 
physical symptoms than those delivered by GPs. Whether 
this superiority is due to a larger number of sessions of PT 
interventions remains unclear from our findings. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Patients presenting with somatic symptoms that lack a 
medical explanation are common in primary and second-
ary health-care settings, with a prevalence of 20–50%  [1–
4] . Such symptoms may be part of psychiatric disorders 
such as anxiety or depression, part of operationally de-
fined syndromes such as chronic fatigue syndrome, ir-
ritable bowel syndrome or fibromyalgia, or simply un-
 Key Words 
 Medically unexplained physical symptoms · Psychological 
interventions · Meta-analysis · Treatment provider · 
Somatization · Symptom severity 
 Abstract 
 Background: Patients with medically unexplained symp-
toms (MUS) are difficult to treat and cause high health-care 
costs. Psychological interventions might be a beneficial op-
tion for treating patients with MUS, but evidence is inconsis-
tent. This meta-analysis compares the effectiveness of psy-
chological interventions for MUS – delivered either by psy-
chotherapists (PTs) or by general practitioners (GPs) – with 
that of usual care.  Method: We conducted a systematic re-
view and meta-analysis on randomised controlled trials of 
psychological interventions for MUS. Physical symptoms 
were the primary outcome, and physical functioning and 
psychological symptoms were the secondary outcomes. We 
pooled between-group effect sizes (ESs) after the treatment 
and at the follow-up in random-effects meta-regressions 
and stratified meta-analyses. We repeated these analyses 
with the intervention provider, intervention dose, MUS se-
verity and methodological quality as predictors of relative 
intervention effects.  Results: A total of 3,225 patients in 20 
studies were analysed. After the treatment, small and sig-
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specific physical symptoms for which no medical ex-
planation could be identified  [3] . The severity of these 
symptoms ranges from single, transient and relatively 
mild symptoms to multiple and/or chronic debilitating 
somatic complaints with poor prognosis  [5, 6] .
 There is an important debate on the classification of 
these health complaints  [7] , the need to distinguish be-
tween medically explained and unexplained symptoms 
 [8] and the clinical relevance of distinguishing between 
individual diagnostic categories  [9, 10] . Accordingly, the 
latest revision of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5)  [11] merged several of the 
previous categories to one diagnosis, i.e. somatic symp-
tom disorder, which places more importance on thoughts, 
feelings and behaviours regarding those symptoms and, 
in contrast to DSM-IV, does not require symptoms to 
lack a medical explanation anymore. The heterogeneity 
of complaints that are combined within the diagnostic 
category of somatic symptom disorder remains high. In 
contrast to DSM-5, the Diagnostic Criteria for Psychoso-
matic Research (DCPR)  [12] suggest a more fine-grain 
diagnostic approach with 12 psychosomatic syndromes 
that capture additional psychosocial variables. The de-
bate on the classification of medically unexplained symp-
toms (MUS) is ongoing  [13, 14] .
 Patients with MUS typically consult a series of physi-
cians and medical specialists – a phenomenon often re-
ferred to as ‘doctor shopping’. This behaviour does not 
relieve the patients’ suffering but increases annual health-
care costs, which are twice as high for patients with MUS 
than for patients without  [15, 16] . Despite the refusal of 
many patients to be treated by psychological means  [17] , 
psychological interventions might be a beneficial treat-
ment option for MUS  [14] and could be a promising ad-
junct to medical treatment  [5] .
 Across systematic reviews and meta-analyses, psycho-
logical interventions for patients with MUS were more 
effective than usual care (UC) or waiting list, albeit with 
small effects  [14, 18–22] . The most recent comprehensive 
meta-analysis  [14] took a broad perspective with a large 
variety of target problems and a large number of analyses. 
In contrast, in this study, we aimed to address one par-
ticular research question. We narrowed down the includ-
ed problems to multiple and unspecific MUS that do not 
relate to a medical or psychiatric disorder or syndrome 
and restricted our analyses to between-group analyses 
comparing a psychological intervention with UC in ran-
domised controlled trials (RCTs). In particular, we looked 
at differential treatment effectiveness, comparing psy-
chological interventions delivered by general practition-
ers (GPs) with those provided by psychotherapists 
(PTs). Additionally, we included the severity of MUS, the 
number of intervention sessions, the length of interven-
tion sessions and the quality of the study methodology as 
potential moderators of relative intervention effects.
 Methods 
 Literature Search 
 We searched bibliographic databases relevant to the field of psy-
chotherapy outcome research (Embase, Medline, PsycINFO, Co-
chrane Controlled Trials Register and PSYNDEX) combining key 
words and text words that relate to psychological interventions, 
RCTs and MUS (online suppl. appendix A; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000380914). The initial 
search was conducted in December 2008. An update search was con-
ducted in January 2013 in the PsycINFO, Medline and Cochrane 
Controlled Trials Register databases. We also checked the reference 
lists of previous systematic reviews and meta-analyses on MUS  [18, 
19, 23] . All records were transferred to EndNote (EndNote X3, 
Thomson Reuters, USA), where duplicates were eliminated and all 
references were screened for inclusion and exclusion criteria.
 Study Selection 
 We included RCTs that evaluated the efficacy of a psychological 
intervention compared to UC in patients with multiple MUS. In 
particular, we included studies if they (a) analysed adult patients (at 
least 80% of patients included had to be older than 18 years) diag-
nosed with MUS (either from patient self-reports or from clinical 
evaluation), (b) compared at least one psychological intervention 
with UC, (c) assigned participants randomly to treatment condi-
tions, and (d) were published as journal articles between January 
1980 and January 2013. Psychological interventions were qualified 
for inclusion if they were implemented at the level of individual 
patients (rather than group, family or couples therapy), included 
face-to-face contact between the participant and the therapist (as 
opposed to telephone- or internet-based interaction between pa-
tient and therapist) and consisted mainly of verbal communication 
(as opposed to, for example, biofeedback or re laxation). We ex-
cluded studies on patients who suffered from functional somatic 
syndromes that focused on one particular organ system (e.g. irri-
table bowel syndrome) or one particular function (e.g. chronic fa-
tigue syndrome). We also excluded studies on hypochondriasis and 
studies that addressed pain as the primary clinical problem (i.e. 
studies were excluded if more than 80% of the patient sample suf-
fered from a pain disorder, such as low back pain). However, we 
included studies if hypochondriasis or pain disorders were one 
among other MUS. No language restrictions were imposed.
 After intensive training, one researcher screened the retrieved 
records and excluded clearly irrelevant references. Two research-
ers then independently reviewed the full text of potentially relevant 
publications. Ambiguities were resolved by consensus with a third 
researcher.
 Outcome Measures 
 The pre-specified primary outcome domain was the presence 
of physical symptoms (i.e. quantity, frequency or intensity). In ad-
dition, we extracted data relating to physical functioning (e.g. self-
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reported functional impairment or quality of life with and without 
relation to physical functioning) and psychological symptoms (e.g. 
depression, anxiety or general psychopathology). We extracted 
post-treatment data (i.e. from the first assessment after the end of 
treatment) and follow-up data (i.e. from the last available assess-
ment after the end of treatment). When more than one outcome 
measure was reported per outcome domain, we extracted the data 
from all reported measures. All outcome data were from self-re-
ports (as opposed to ratings by clinicians).
 Coding and Data Extraction 
 We assessed the profession of the intervention provider, the 
severity of physical symptoms as well as the type and dose of the 
intervention as clinically relevant characteristics of the included 
studies. The profession of the intervention provider was classified 
as either PT (mental health professionals, including PTs and psy-
chiatrists) or GP (professionals in primary health-care service, in-
cluding nurse practitioners and medical doctors). Patient samples 
were considered severe if all patients met the criteria of SSI 4,6  [24] , 
suffered from somatisation disorder according to DSM-IV criteria 
or reported 5 MUS at minimum. Patient samples were considered 
non-severe if fewer MUS were present or the number of MUS was 
unclear. Interventions were classified into three pre-specified cat-
egories: cognitive-behavioural treatment approaches (when the 
psychological intervention was based on a cognitive-behavioural 
rationale, e.g. reattribution), other psychological interventions 
(e.g. disclosure intervention or psychodynamic therapy) and en-
hanced care (i.e. a case manager or health educator assisted the 
GP). We then assessed the number of sessions as well as the length 
of sessions as indicators of the intervention dose.
 We considered the concealment of treatment allocation  [25, 
26] and the adequacy of analyses  [27] as indicators of the method-
ological quality of the included studies. The concealment of alloca-
tion was considered adequate if the investigators responsible for 
patient selection could not foresee which treatment would be next 
before allocating patients to treatments. Analyses were considered 
adequate if all recruited patients were analysed in the group to 
which they were originally allocated, regardless of the intervention 
they had received (ITT principle). Analyses were considered inad-
equate if effect sizes (EFs) could not be calculated on the total ran-
domised sample.
 All data were extracted in duplicate on a standardised and com-
puterised form in Epidata 3.1 (The Epidata Association, Denmark) 
by 2 independent investigators (M.H. and a MSc student). Both 
investigators were trained in a 2-day workshop with a manual that 
included operational descriptions of all relevant data. Disagree-
ments were resolved by consensus.
 Data Analysis 
 Standardised mean differences (d) were calculated with small 
sample corrections, as recommended by Hedges and Olkin  [28] . 
ESs of 0.20, 0.50 and 0.80 were considered as small, moderate, and 
large, respectively  [29] . If standard deviations were not provided, 
ESs were computed by transforming other statistics (e.g. standard 
errors, confidence intervals or other indicators). We used the for-
mulas provided by Lipsey and Wilson  [30] . ESs were calculated for 
post-treatment and follow-up data for each outcome domain. In 
cases where multiple measures were reported per outcome do-
main, we averaged the ESs and calculated the standard errors using 
the mean number of patients across measures. Results from ITT 
analyses were preferred to analyses based on treatment completers 
only, because ITT analyses have been shown to provide more con-
servative results compared to completer analyses  [31] .
 We applied standard inverse variance-weighted random-ef-
fects meta-analyses in order to quantify the overall intervention 
effect and the overall heterogeneity between primary studies. p val-
ues for interaction effects were derived from random-effects meta-
regressions using a residual maximum likelihood to estimate the 
additive (between-study) component of variance τ 2 . Standard er-
rors were calculated using the method developed by Knapp and 
Hartung  [32] and were tested for statistical significance (two-
tailed) with the t distribution. Using this procedure in meta-re-
gression reduces false-positive rates compared to z tests  [33] .
 We first conducted meta-analyses without including any pre-
dictor for each type of outcome domain and for post-treatment 
and follow-up data. We then performed outlier analyses by draw-
ing Galbraith plots. We excluded studies from further analyses if 
(a) they were clearly identified as outliers by the outlier analysis 
and (b) if the confidence intervals of the respective study did not 
overlap with the confidence interval of the overall effect estimate.
 We then included the potential moderators as single predictors 
in meta-regression analyses and conducted stratified meta-analy-
ses. In case of more than one significant moderator per outcome 
domain, we checked for potential interaction effects between the 
significant moderators by performing multiple meta-regressions, 
including significant study characteristics as predictors as well as 
an interaction term (according to Shadish and Sweeney  [34] ). In 
addition, we checked for colinearity among significant predictors 
by examining pairwise correlations.
 Heterogeneity of the ES within each outcome domain between 
the studies was assessed by τ 2  [35, 36] . Higher τ 2 values indicate 
greater variability between studies than would be expected due to 
chance alone. Based on our definition of small, moderate and large 
differences between interventions, we classified τ 2 as follows: τ 2 = 
(0.2/2) 2 = 0.01 was considered to represent low heterogeneity, τ 2 = 
0.0625 [(0.5/2) 2 ] moderate heterogeneity and τ 2 = 0.16 [(0.8/2) 2 ] 
high heterogeneity between studies. τ 2 has been shown to be inde-
pendent of the number of studies and the number of patients in-
cluded in the meta-analysis (i.e. no increase with large numbers of 
studies or large sample sizes)  [35, 36] .
 Meta-analyses and meta-regressions were performed with the 
software package STATA 11.2 using the commands ‘metan’ and 
‘metareg’  [37] . We explored the presence of the small sample bias 
by assessing funnel plot asymmetry with a regression test  [38] , 
which was performed with the ‘metabias’ procedure.
 Results 
 Twenty studies met the inclusion criteria for the pres-
ent meta-analysis  [39–58] . We identified 850 records 
through database searching and screening of reference 
lists of previous systematic reviews and meta-analyses. 
We screened 675 records by title and abstract after dupli-
cates had been removed. Of the 114 full-text articles that 
were assessed for eligibility, 6 were excluded as they were 
multiple publications of one and the same study, and a 
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further 88 were excluded because the population, the in-
tervention, the study type or the study design did not 
match the inclusion criteria (see online suppl. appendix 
B for the flow chart of study selection).
 Study Characteristics 
 A total of 3,225 patients were randomised to interven-
tions, with a median of 117 patients per study (range: 10–
911). The characteristics of the included studies are sum-
marised in online supplementary appendix C. One study 
was published in 1995, whereas all other studies were 
published between 2000 and 2010. Thirteen studies were 
carried out in Europe, 4 in the US, 2 in Sri Lanka, and 1 
study was carried out in Australia. Physical symptoms 
were assessed in 14 studies, physical functioning in 15 and 
psychological symptoms also in 15. Follow-up assess-
ments were available in 11 studies. Time points of follow-
up assessments varied between 6 and 24 months after be-
ginning the intervention.
 In 11 studies, at least some patients reported comorbid 
mental disorders. In 9 studies, some of the patients faced 
a difficult living situation (e.g. unemployment). Howev-
er, only in a minority of the samples (6 of 21 studies) did 
more than 80% of the patients report additional problems 
(i.e. mental disorder or living situation; see online suppl. 
appendix C). Nine studies were classified as including pa-
tients with severe MUS, whereas 11 studies were classified 
as including patient samples with non-severe MUS.
 Patients were treated by GPs in 13 studies and by PTs 
in 7 studies. Psychological interventions were based on 
CBT approaches in 11 studies, on other psychological 
interventions in 5 studies and on enhanced care in 4 
studies. In all studies, UC was used as a control group. 
The median number of sessions per study was 6 (range: 
2–15), and the reported mean length of a session of
psychological interventions was 41 min (range: 13–70). 
Studies varied across intervention providers with re-
gard to the number of sessions (median of 9 for PTs and 
median of 5 for GPs) and the length of sessions (mean 
of 49 min for PTs and mean of 33 min for GPs). The 
correlation between the number of sessions and the 
treatment provider was small to moderate (r = 0.34, 
p = 0.23), and the correlation between the session length 
and the treatment provider was moderate (r = 0.48, 
p = 0.08).
 In terms of methodological quality, 13 studies report-
ed data from ITT analyses and 7 studies reported ade-
quate strategies for concealment of allocation of patients 
to interventions. Only 4 studies fulfilled both criteria of 
higher quality.
 Overall Effectiveness 
 At the end of the intervention, the relative effect be-
tween psychological interventions and UC was small for 
physical symptoms (d = 0.22; k  =  14; 95% CI 0.04, 0.40;
p = 0.02), physical functioning (d = 0.19; k = 15; 95% CI 
0.02, 0.36; p = 0.03) and psychological symptoms (d = 
0.13; k = 15; 95% CI –0.00, 0.27; p = 0.05). Heterogeneity 
was moderate to low (τ 2 = 0.07 for physical symptoms and 
physical functioning, and τ 2 =  0.03 for psychological 
symptoms). For physical symptoms, 1 study was identi-
fied as an outlier (i.e. van der Feltz-Cornelis et al.  [58] for 
physical symptoms; see online suppl. appendix D). The 
removal of the outlier slightly reduced the relative effect 
as well as the heterogeneity for physical symptoms (d = 
0.15; k = 13; 95% CI 0.00, 0.30; τ 2 = 0.03). The effect re-
mained statistically significant (p = 0.048).
 At the follow-up, the relative effect between psycho-
logical interventions and UC was small but not statisti-
cally significant (d = 0.21; k = 11; 95% CI –0.02, 0.44; p = 
0.08 for physical symptoms; d = 0.13; k = 10; 95% CI 
–0.04, 0.30; p = 0.13 for physical functioning; and d = 
–0.05; k = 9; 95% CI –0.18, 0.08; p = 0.47 for psychologi-
cal symptoms). Heterogeneity was moderate to high  for 
physical symptoms (τ 2 = 0.11), low to moderate for phys-
ical functioning (τ 2 = 0.04) and low for psychological 
symptoms (τ 2 = 0.01). The study of van der Feltz-Corne-
lis et al.  [58] was again identified as an outlier for physical 
symptoms and physical functioning. Excluding this out-
lier reduced the relative effect between psychological in-
terventions and UC (d = 0.08; k = 10; 95% CI –0.05, 0.21 
for physical symptoms; and d = 0.05; k = 9; 95% CI –0.07, 
0.17 for physical functioning). Neither effect was statisti-
cally significant (all p > 0.20). Heterogeneity was low with 
 τ 2 = 0.01 for all three outcome domains.
 Some funnel plots suggested asymmetry, indicating 
that smaller studies showed larger effects of psychological 
interventions compared with UC. However, the corre-
sponding regression test was significant for psychological 
symptoms after the treatment only (p = 0.01; all other p > 
0.12). Heterogeneity was considerably reduced after ex-
cluding the outlier. Therefore, we excluded the study by 
van der Feltz-Cornelis et al.  [58] from the moderator 
analyses of physical symptoms after the treatment and at 
follow-up as well as from moderator analyses of physical 
functioning at follow-up.
 Moderator Analyses 
 Table 1 shows the results from meta-regressions, in-
cluding the methodological and clinical characteristics as 
single predictors. For physical symptoms, significant 
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moderating effects were found for the provider of the in-
tervention (p = 0.02) and for the number of sessions (p = 
0.03). Superiority of psychological interventions over UC 
was larger in studies in which PTs delivered the interven-
tion ( fig. 1 ) and in studies with a higher number of ses-
sions. None of the other predictors included had a sig-
nificant moderating effect on the relative intervention
effect for our secondary outcomes, namely, physical func-
tioning or psychological symptoms (all p > 0.27). At fol-
low-up, the results obtained after the treatment were con-
firmed: the provider of the intervention and the number 
of sessions were the only significant moderators (p = 0.03 
in both cases) for the primary outcome, and there were 
no significant moderators for the secondary outcomes.
 Additional Exploratory Analyses 
 We restricted the following exploratory analyses to the 
primary outcome (i.e. physical symptoms) for which the 
intervention provider and the session number were sig-
nificant moderators. First, we tested for a possible inter-
action between the intervention provider and the inter-
vention dose.  Table 2 presents the results from meta-re-
gressions that investigated whether the association of the 
number of sessions with outcome was the same for GPs 
and PTs. Therefore, the analyses were stratified for the 
intervention provider and included the number of ses-
sions as covariate. When testing for the interaction in a 
multiple meta-regression, neither the two predictors nor 
the interaction term was statistically significant (all p > 
0.39 after the treatment and all p > 0.54 at follow-up).
 In a final exploratory analysis, we checked for an inter-
action between the intervention provider and MUS sever-
ity, although severity was not a significant moderator of 
the intervention effect.  Table 2 presents the results from 
meta-regressions that investigated whether the superior-
ity of PTs over GPs depended on symptom severity. 
Therefore, the analyses were stratified according to MUS 
severity at the beginning of the psychological interven-
 Table 1.  Results from meta-regressions after the treatment including clinical and methodological study characteristics as moderators of 
relative effects between psychological interventions and UC
Outcome dimension After treatment  At follow-up
k B 95% CI τ2 p  k B 95% CI τ2 p
Physical symptoms
Provider 13 0.32 0.07, 0.57 0.00 0.02 10 0.29 0.04, 0.53 0.00 0.03
Severity 13 0.02 –0.41, 0.45 0.04 0.93 10 0.07 –0.37, 0.51 0.02 0.73
Number of sessionsa 11 0.06 0.01, 0.11 0.00 0.03 9 0.05 0.01, 0.10 0.00 0.03
Session lengthb 11 –0.06 –0.92, 0.81 0.05 0.88 9 0.19 –0.62, 1.00 0.03 0.60
Concealment 13 –0.05 –0.43, 0.33 0.04 0.79 10 –0.09 –0.44, 0.27 0.01 0.59
ITT 13 0.12 –0.27, 0.51 0.04 0.52 10 0.12 –0.21, 0.45 0.01 0.42
Physical functioning
Provider 15 –0.05 –0.48, 0.38 0.07 0.80 9 0.19 –0.13, 0.50 0.01 0.20
Severity 15 –0.19 –0.55, 0.17 0.06 0.27 9 –0.11 –0.45, 0.22 0.01 0.45
Number of sessionsa 10 0.04 –0.03, 0.10 0.03 0.27 7 0.04 –0.02, 0.09 0.00 0.16
Session lengthb 9 –0.06 –0.77, 0.64 0.04 0.84 7 –0.40 –1.12, 0.32 0.00 0.21
Concealment 15 –0.11 –0.49, 0.27 0.07 0.54 9 –0.11 –0.45, 0.23 0.01 0.46
ITT 15 –0.06 –0.44, 0.33 0.07 0.76 9 0.18 –0.09, 0.46 0.01 0.16
Psychological symptoms
Provider 15 0.11 –0.22, 0.44 0.02 0.48 9 0.11 –0.24, 0.45 0.01 0.50
Severity 15 –0.14 –0.43, 0.16 0.02 0.33 9 0.06 –0.36, 0.48 0.02 0.74
Number of sessionsa 12 0.01 –0.03, 0.05 0.02 0.47 8 0.01 –0.05, 0.08 0.03 0.60
Session lengthb 12 0.02 –0.45, 0.49 0.00 0.93 8 0.48 –0.16, 1.12 0.00 0.12
Concealment 15 –0.03 –0.34, 0.27 0.03 0.82 9 0.10 –0.28, 0.47 0.02 0.56
ITT 15 –0.07 –0.40, 0.26 0.03 0.66 9 –0.05 –0.44, 0.33 0.02 0.75
 B = Regression coefficient from meta-regression; k = number of included study ESs; τ2 = variability between studies. Significant p 
values are printed in bold.
a Continuous variable (range: 2 – 15 sessions). b Continuous variable (range: 0.22 – 1.17 h).
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Physical symptoms
Post-treatment
PT
GP
Follow-up
PT
GP
Physical functioning
Post-treatment
PT
GP
Follow-up
PT
GP
Psychological Symptoms
Post-treatment
PT
GP
Follow-up
PT
GP
Outcome dimension
 0.15 (0.00, 0.30)
 0.32 (0.13, 0.51)
 0.00 (–0.14, 0.15)
 0.08 (–0.05, 0.21)
 0.26 (0.06, 0.46)
–0.02 (–0.13, 0.09)
 0.19 (0.02, 0.36)
 0.14 (–0.05, 0.34)
 0.21 (–0.01, 0.43)
 0.05 (–0.07, 0.17)
 0.17 (0.02, 0.37)
–0.00 (–0.17, 0.16)
 0.13 (–0.00, 0.27)
 0.22 (–0.08, 0.53)
 0.09 (–0.05, 0.23)
–0.05 (–0.18, 0.08)
 0.01 (–0.24, 0.26)
–0.09 (–0.23, 0.06)
    ES (95% CI)
Favours UC  Favours psychological intervention 
–0.5 0–0.25 0.25 0.5 0.75
 Fig. 1. Relative effects between psychologi-
cal interventions and UC (overall and strat-
ified according to the intervention provid-
er, i.e. GP vs. PT). Positive ESs indicate su-
periority of the psychological intervention. 
 Table 2.  Results from stratified meta-regressions to detect possible interactions between predictors of relative effects and psychological 
interventions and UC for physical symptoms
Predictor  After treatment At follow-up
 k B 95% CI τ2 p  k B 95% CI τ2 p
Number of sessions
GPa 5 0.10 –0.17, 0.37 0.03 0.33 4 –0.01 –0.34, 0.32 0.00 0.94
PTb 6 0.03 –0.09, 0.15 0.01 0.48 5 0.05 –0.08, 0.17 0.00 0.31
Provider
Non-severe 5 0.15 –1.40, 1.69 0.18 0.78 3 0.51 –5.28, 6.29 0.08 0.47
Severe 8 0.34 0.06, 0.62 0.00 0.02 7 0.30 –0.01, 0.61 0.00 0.06
 B = Regression coefficient from meta-regression; k = number of included study ESs; τ2 = variability between studies within one stra-
tum. Significant p values are printed in bold.
a Range of the continuous covariate ‘number of sessions’ in the GP stratum: 2 – 15. b Range of the continuous covariate ‘number of 
sessions’ in the PT stratum: 4 – 12.
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tion and included the intervention provider as covariate. 
PTs had larger effects (d = 0.35; 95% CI 0.14, 0.55; τ 2 = 
0.00; k = 4) than GPs in studies with severe MUS (d = 0.01; 
95% CI –0.10, 0.12; τ 2 = 0.00; k = 4; p for interaction = 
0.02) but not in studies with non-severe MUS (p for in-
teraction  = 0.78). When we entered severity and provider 
in addition to an interaction term in a multiple meta-re-
gression, however, neither predictor remained statistical-
ly significant (all p > 0.69). At follow-up, the results found 
after the intervention were confirmed, with PTs showing 
larger effects than GPs only in studies with severe MUS 
samples. Psychological interventions were significantly 
more effective than UC when provided by PTs in samples 
with severe MUS (d = 0.29; 95% CI 0.06, 0.53; τ 2 = 0.01;
k = 3), but there was no difference between psychological 
interventions and UC when psychological interventions 
were provided by GPs (d = –0.01; 95% CI –0.11, 0.10;
τ 2 = 0.00; k = 4). This difference in relative intervention 
effects between PTs and GPs in the severe MUS samples 
was only borderline significant (p for interaction = 0.06). 
In contrast, no difference was found between GPs and 
PTs in the studies with non-severe samples (p for interac-
tion = 0.47). In the multiple meta-regression based on the 
follow-up data, again, neither predictor was statistically 
significant (all p > 0.27).
 Discussion 
 Psychological interventions were more effective than 
UC for physical symptoms, physical functioning and psy-
chological symptoms after treatment termination ( fig. 1 ). 
The superiority of psychological interventions over UC in 
reducing physical symptoms was more pronounced when 
the intervention was delivered by PTs than by GPs. This 
pattern appears in most of the conducted analyses ( fig. 1 ). 
However, only for physical symptoms assessed after the 
treatment was the pattern statistically significant. An ex-
ploratory analysis revealed that PT interventions were su-
perior to GP interventions, particularly for patients with 
severe MUS. In contrast, similar intervention effects were 
found for patients with non-severe MUS when psycho-
logical interventions were delivered either by PTs or GPs. 
However, as the number of sessions was also associated 
with relative intervention effects, it is possible that the 
impact of the intervention provider on the outcome is 
confounded with a dose effect (see below). Interestingly, 
the session length was not associated with intervention 
effects. We found no robust evidence for long-term inter-
vention effects. Besides the outlier, only 2 out of 11 stud-
ies showed a significant long-term effect of psychological 
interventions on physical symptoms, and no study 
showed significant long-term effects on physical func-
tioning or psychological symptoms (see online suppl. ap-
pendix E).
 Our results confirm the general conclusion of recent 
meta-analyses  [14, 18] that psychological interventions 
are effective treatments for MUS, albeit with small ESs. 
Small between-group ESs may be explained by a large 
amount of improvement of MUS in UC or even without 
treatment  [6, 59] . The somewhat smaller ES in our meta-
analysis compared with the previous ones may be ex-
plained by our restriction to RCTs when compared with 
Kleinstäuber et al.  [18] and by excluding waiting list as 
comparator when compared with van Dessel et al.  [14] . 
The particularly low ES for physical functioning and psy-
chological symptoms may be a consequence of inade-
quate assessment. In future studies, the use of assessment 
tools that are based on the DCPR, which has been shown 
to be highly sensitive in identifying psychological distress 
and characterizing patients’ psychological response to 
medical illness  [60, 61] , might reveal larger effects par-
ticularly on psychosocial variables as outcome. Our re-
sults suggest that patients with severe MUS should be 
treated by PTs, which is in line with a recent trial  [62] . In 
contrast, patients with non-severe MUS may be treated 
by either PTs or GPs. The need for more elaborated treat-
ments for patients with severe MUS is also reflected by the 
previous finding that those patients with MUS who have 
a larger number of symptoms at baseline show less im-
provement in UC or without treatment  [6] .
 Several aspects need attention when trying to explain 
the superiority of PT-delivered interventions over GP in-
terventions. On the one hand, when compared to GPs, PTs 
might offer additional explanations for MUS and thus 
contribute to increasing the patients’ ability to tolerate 
symptoms  [63] . On the other hand, patients seeking sup-
port from GPs may differ in their motivation from those 
who seek support from PTs  [64, 65] . Those patients who 
seek treatment by a PT may, for instance, be more moti-
vated to change, or may be more open to changing their 
illness perception, which in turn might influence a pa-
tient’s experience and behaviour  [66] . Finally, the superi-
ority of PTs might be due to a dose difference between PT 
and GP psychological interventions: in particular, patients 
with higher symptom severity may benefit from a higher 
intervention dose. In our analyses, the number of sessions 
was indeed higher in studies with PTs than in studies with 
GPs. When trying to disentangle the effects of the two po-
tential moderators (dose and provider), we found no evi-
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dence of a strong collinearity, neither did we find evidence 
of an interaction effect of both variables on the outcome. 
However, the multiple meta-regressions may have lacked 
the power to reveal statistically significant interaction ef-
fects. Thus, our results document the superiority of PT in-
terventions over GP interventions without offering an ex-
planation. Further studies should address the outlined is-
sues by directly comparing psychological interventions 
that are delivered by PTs versus those delivered by GPs. In 
addition, explorations of the possible mechanisms that un-
derlie the superiority of PTs over GPs may include ma-
nipulating the number of sessions, controlling patients’ 
self-selection of PTs or GPs, and controlling the rationale 
that therapists offer their patients as explanation for their 
symptoms. The interesting finding that only the number 
of sessions, but not the session length is associated with 
intervention effects needs further attention.
 Some limitations need to be considered when inter-
preting the results presented. First, we excluded studies 
on somatoform pain disorder. It has been previously 
shown that, particularly in studies on pain, the question 
of whether the symptoms indeed lack a symptomatic pa-
thology remains unclear  [67] . We therefore excluded 
studies that primarily addressed pain and came up with a 
pool of included studies with only small to moderate be-
tween-study heterogeneity of ES estimates. Before gener-
alizing our results to patient populations that were not 
included in our meta-analysis, the results presented here 
need to be replicated in the respective patient popula-
tions. Second, we refrained from analysing additional po-
tential moderators in order to minimise the number of 
false-positive results due to multiple testing. We restrict-
ed the number of moderators to variables that were ade-
quately reported in the included studies or known to be 
relevant predictors of the effectiveness of psychological 
interventions for MUS. We cannot rule out the possibil-
ity that additional moderators may have affected inter-
vention effects. However, heterogeneity statistics indicat-
ed low between-study heterogeneity in the final analyses 
and thus imply no need to explore additional potential 
moderators. Third, we did not pool data regarding health-
care utilisation and dropout rates. Indicators of health-
care utilisation vary largely across individual studies (e.g. 
assessment of visits to GPs and specialists, costs of medi-
cation or number of hospitalisation days), and the report-
ing of dropout rates mostly does not allow distinguishing 
between patients who refused to complete the interven-
tion and those who refused only the outcome assessment. 
Thus, the validity of both outcome domains remains un-
clear. Fourth, the results based on differentiating between 
studies on severe versus non-severe MUS should be re-
garded as preliminary. The distinction between severe 
and non-severe patient samples was done on an explor-
atory basis and did not take into account results from sub-
group analyses in primary studies, such as for example the 
one reported by Toft et al.  [57] . Further confirmation of 
the observed patterns is absolutely essential. Finally, the 
number of included studies was somewhat small due to 
our rather strict inclusion criteria in order to get a homo-
geneous pool of studies with similar complaints. The re-
sults from our stratified analyses therefore lack precision 
in many cases and need to be confirmed in primary stud-
ies that are designed and adequately sized in order to test 
the respective research questions. In order to use as much 
data as possible, we approximated the ES estimate in one 
case in which the authors reported that ‘The general pat-
tern was the same at six and 12 month follow ups (data 
not shown)’ [ 50 , p. 4]. In this case, we used the same data 
for the calculation after the treatment and at follow-up. 
Excluding the approximated data in the respective sensi-
tivity analyses led to a slightly reduced precision but did 
not change the findings.
 From a clinical perspective, our results suggest that pa-
tients with MUS who did not respond to UC should be 
treated with psychological interventions, although all in-
tervention effects were small. For those patients who have 
suffered from their symptoms for a long time and are de-
scribed as treatment resistant, even small and short-term 
intervention effects, indicating some symptom change 
over even a short period of time, can be regarded as clin-
ically relevant. Short-term improvement could serve as a 
first step that may contribute to reappraisals of the MUS 
and eventually stimulate changes in health behaviour  [66, 
68] . In this sense, psychological interventions in particu-
lar may contribute to challenging the perception of many 
MUS patients that change is impossible  [69] . There is, 
however, potential for improvement in the treatment of 
patients with MUS. Complex treatment packages includ-
ing psychological as well as technologically driven inter-
ventions, which focus on psychophysiology, have recent-
ly shown promising results  [70] . Whether such complex 
treatment regimen for MUS may lead to better or more 
long-lasting improvement should be addressed further in 
well-designed primary studies.
 To conclude, this meta-analysis shows that psycholog-
ical interventions are promising for patients with MUS. 
The psychological interventions of PTs are more effective 
in treating unexplained physical symptoms than those 
delivered by GPs. The collaboration between GPs and 
PTs may be important for the successful treatment of 
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MUS and particularly for treating patients with severe 
MUS. Such collaborative interventions have been shown 
to be superior compared to enhanced care of GPs alone 
 [71] . Our analyses pointed out several research questions, 
including the apparent differential need for the treatment 
of patients with severe versus non-severe MUS, which re-
main inadequately answered to date.
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